Loading…

Sildenafil in the Treatment of Antipsychotic-Induced Erectile Dysfunction: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Two-Way Crossover Trial

OBJECTIVE: Antipsychotic-induced erectile dysfunction is a significant clinical problem and is a common reason for poor medication compliance. This report studied the efficacy and tolerability of sildenafil citrate in patients with antipsychotic-induced erectile dysfunction. METHOD: The study design...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of psychiatry 2006-03, Vol.163 (3), p.494-499
Main Authors: Gopalakrishnan, Rajesh, Jacob, K.S., Kuruvilla, Anju, Vasantharaj, B., John, Jacob K.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a495t-6de107c31408e66a4fc74f82f89551d825cc94bcddb5a98c0b7d06c885faf30a3
cites cdi_FETCH-LOGICAL-a495t-6de107c31408e66a4fc74f82f89551d825cc94bcddb5a98c0b7d06c885faf30a3
container_end_page 499
container_issue 3
container_start_page 494
container_title The American journal of psychiatry
container_volume 163
creator Gopalakrishnan, Rajesh
Jacob, K.S.
Kuruvilla, Anju
Vasantharaj, B.
John, Jacob K.
description OBJECTIVE: Antipsychotic-induced erectile dysfunction is a significant clinical problem and is a common reason for poor medication compliance. This report studied the efficacy and tolerability of sildenafil citrate in patients with antipsychotic-induced erectile dysfunction. METHOD: The study design was a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial carried out at a tertiary referral center. Thirty-two married male outpatients with schizophrenia or delusional disorder and antipsychotic-induced erectile dysfunction were recruited for the trial. Sexual function was assessed from patient logs of sexual activity. RESULTS: Thirty-two subjects and their spouses, who agreed to take part in the study, were included in the crossover trial. Thirty-one (96.9%) completed the trial. There was no significant period effect or treatment-period interaction. Patients reported significant improvement while taking sildenafil in the number of adequate erections, satisfaction with sexual intercourse, and the duration of erections over 2 weeks. The odds ratios for adequate erections and for satisfactory sexual intercourse with sildenafil were 4.07 and 3.77, respectively. The effect of sildenafil remained significant even after adjustment for period and week effects and treatment-period interaction with Poisson regression analysis. There were no major side effects or adverse drug interactions. CONCLUSIONS: Sildenafil citrate is safe and effective in the treatment of antipsychotic-induced erectile dysfunction. It is also well tolerated.
doi_str_mv 10.1176/appi.ajp.163.3.494
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_19727888</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1005829321</sourcerecordid><originalsourceid>FETCH-LOGICAL-a495t-6de107c31408e66a4fc74f82f89551d825cc94bcddb5a98c0b7d06c885faf30a3</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhiMEoqXwAhyQhQSnZms7ceJwW3ZbqFQJBIvgZjn2WPXKawc7AZa34U1x2BWVOHCyR_pm5h99RfGU4AUhbXMhh8Eu5HZYkKZaVIu6q-8Vp4RVrGwp5feLU4wxLTtWfTkpHqW0zSWuWvqwOCENIxVv6Wnx66N1Grw01iHr0XgLaBNBjjvwIwoGLf1oh7RXt2G0qrz2elKg0WUENVoHaL1PZvL5H_wrtEQfpNdhZ3-CPkfrMPUOytfO-ly9d1JBH8pV8GMMzs3ElYMfdmbWIcE52nwP5We5R6sYUgrfIOYkVrrHxQMjXYInx_es-HR1uVm9LW_evbleLW9KWXdsLBsNBLeqIjXm0DSyNqqtDaeGd4wRzSlTqqt7pXXPZMcV7luNG8U5M9JUWFZnxcvD3CGGrxOkUexsUuCc9BCmJEjX0pZznsHn_4DbMEWfswlKMcMNrmeIHiA1XxPBiCHanYx7QbCY7YnZnsj2RLYnKpHt5aZnx8lTvwN913LUlYEXR0AmJZ2J0iub7riWccLoPOjiwP1Z8jfef1b_Bv1UtgM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220506048</pqid></control><display><type>article</type><title>Sildenafil in the Treatment of Antipsychotic-Induced Erectile Dysfunction: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Two-Way Crossover Trial</title><source>American Psychiatric Publishing Journals (1997-Present)</source><creator>Gopalakrishnan, Rajesh ; Jacob, K.S. ; Kuruvilla, Anju ; Vasantharaj, B. ; John, Jacob K.</creator><creatorcontrib>Gopalakrishnan, Rajesh ; Jacob, K.S. ; Kuruvilla, Anju ; Vasantharaj, B. ; John, Jacob K.</creatorcontrib><description>OBJECTIVE: Antipsychotic-induced erectile dysfunction is a significant clinical problem and is a common reason for poor medication compliance. This report studied the efficacy and tolerability of sildenafil citrate in patients with antipsychotic-induced erectile dysfunction. METHOD: The study design was a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial carried out at a tertiary referral center. Thirty-two married male outpatients with schizophrenia or delusional disorder and antipsychotic-induced erectile dysfunction were recruited for the trial. Sexual function was assessed from patient logs of sexual activity. RESULTS: Thirty-two subjects and their spouses, who agreed to take part in the study, were included in the crossover trial. Thirty-one (96.9%) completed the trial. There was no significant period effect or treatment-period interaction. Patients reported significant improvement while taking sildenafil in the number of adequate erections, satisfaction with sexual intercourse, and the duration of erections over 2 weeks. The odds ratios for adequate erections and for satisfactory sexual intercourse with sildenafil were 4.07 and 3.77, respectively. The effect of sildenafil remained significant even after adjustment for period and week effects and treatment-period interaction with Poisson regression analysis. There were no major side effects or adverse drug interactions. CONCLUSIONS: Sildenafil citrate is safe and effective in the treatment of antipsychotic-induced erectile dysfunction. It is also well tolerated.</description><identifier>ISSN: 0002-953X</identifier><identifier>EISSN: 1535-7228</identifier><identifier>DOI: 10.1176/appi.ajp.163.3.494</identifier><identifier>PMID: 16513872</identifier><identifier>CODEN: AJPSAO</identifier><language>eng</language><publisher>Washington, DC: American Psychiatric Publishing</publisher><subject>3',5'-Cyclic-GMP Phosphodiesterases - therapeutic use ; Adult ; Antipsychotic Agents - adverse effects ; Biological and medical sciences ; Clinical trials ; Comorbidity ; Cross-Over Studies ; Diabetes ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Administration Schedule ; Drug therapy ; Erectile Dysfunction - chemically induced ; Erectile Dysfunction - drug therapy ; Erectile Dysfunction - epidemiology ; Follow-Up Studies ; Humans ; Male ; Medical sciences ; Middle Aged ; Neuropharmacology ; Patients ; Pharmacology. Drug treatments ; Physical examinations ; Piperazines - therapeutic use ; Placebos ; Prolactin - blood ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Purines ; Regression Analysis ; Schizophrenia ; Schizophrenia - drug therapy ; Schizophrenia - epidemiology ; Schizophrenia, Paranoid - drug therapy ; Schizophrenia, Paranoid - epidemiology ; Schizophrenia, Paranoid - psychology ; Sexual behavior ; Sexual Behavior - psychology ; Sexual disorders ; Sildenafil Citrate ; Sulfones ; Treatment Outcome</subject><ispartof>The American journal of psychiatry, 2006-03, Vol.163 (3), p.494-499</ispartof><rights>2006 INIST-CNRS</rights><rights>Copyright American Psychiatric Association Mar 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a495t-6de107c31408e66a4fc74f82f89551d825cc94bcddb5a98c0b7d06c885faf30a3</citedby><cites>FETCH-LOGICAL-a495t-6de107c31408e66a4fc74f82f89551d825cc94bcddb5a98c0b7d06c885faf30a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://psychiatryonline.org/doi/epdf/10.1176/appi.ajp.163.3.494$$EPDF$$P50$$Gappi$$H</linktopdf><linktohtml>$$Uhttps://psychiatryonline.org/doi/full/10.1176/appi.ajp.163.3.494$$EHTML$$P50$$Gappi$$H</linktohtml><link.rule.ids>314,776,780,2841,21606,21607,21608,27903,27904,77541,77546</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=17581524$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16513872$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gopalakrishnan, Rajesh</creatorcontrib><creatorcontrib>Jacob, K.S.</creatorcontrib><creatorcontrib>Kuruvilla, Anju</creatorcontrib><creatorcontrib>Vasantharaj, B.</creatorcontrib><creatorcontrib>John, Jacob K.</creatorcontrib><title>Sildenafil in the Treatment of Antipsychotic-Induced Erectile Dysfunction: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Two-Way Crossover Trial</title><title>The American journal of psychiatry</title><addtitle>Am J Psychiatry</addtitle><description>OBJECTIVE: Antipsychotic-induced erectile dysfunction is a significant clinical problem and is a common reason for poor medication compliance. This report studied the efficacy and tolerability of sildenafil citrate in patients with antipsychotic-induced erectile dysfunction. METHOD: The study design was a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial carried out at a tertiary referral center. Thirty-two married male outpatients with schizophrenia or delusional disorder and antipsychotic-induced erectile dysfunction were recruited for the trial. Sexual function was assessed from patient logs of sexual activity. RESULTS: Thirty-two subjects and their spouses, who agreed to take part in the study, were included in the crossover trial. Thirty-one (96.9%) completed the trial. There was no significant period effect or treatment-period interaction. Patients reported significant improvement while taking sildenafil in the number of adequate erections, satisfaction with sexual intercourse, and the duration of erections over 2 weeks. The odds ratios for adequate erections and for satisfactory sexual intercourse with sildenafil were 4.07 and 3.77, respectively. The effect of sildenafil remained significant even after adjustment for period and week effects and treatment-period interaction with Poisson regression analysis. There were no major side effects or adverse drug interactions. CONCLUSIONS: Sildenafil citrate is safe and effective in the treatment of antipsychotic-induced erectile dysfunction. It is also well tolerated.</description><subject>3',5'-Cyclic-GMP Phosphodiesterases - therapeutic use</subject><subject>Adult</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Clinical trials</subject><subject>Comorbidity</subject><subject>Cross-Over Studies</subject><subject>Diabetes</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Drug therapy</subject><subject>Erectile Dysfunction - chemically induced</subject><subject>Erectile Dysfunction - drug therapy</subject><subject>Erectile Dysfunction - epidemiology</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>Patients</subject><subject>Pharmacology. Drug treatments</subject><subject>Physical examinations</subject><subject>Piperazines - therapeutic use</subject><subject>Placebos</subject><subject>Prolactin - blood</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Purines</subject><subject>Regression Analysis</subject><subject>Schizophrenia</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenia - epidemiology</subject><subject>Schizophrenia, Paranoid - drug therapy</subject><subject>Schizophrenia, Paranoid - epidemiology</subject><subject>Schizophrenia, Paranoid - psychology</subject><subject>Sexual behavior</subject><subject>Sexual Behavior - psychology</subject><subject>Sexual disorders</subject><subject>Sildenafil Citrate</subject><subject>Sulfones</subject><subject>Treatment Outcome</subject><issn>0002-953X</issn><issn>1535-7228</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNp9kcFu1DAQhiMEoqXwAhyQhQSnZms7ceJwW3ZbqFQJBIvgZjn2WPXKawc7AZa34U1x2BWVOHCyR_pm5h99RfGU4AUhbXMhh8Eu5HZYkKZaVIu6q-8Vp4RVrGwp5feLU4wxLTtWfTkpHqW0zSWuWvqwOCENIxVv6Wnx66N1Grw01iHr0XgLaBNBjjvwIwoGLf1oh7RXt2G0qrz2elKg0WUENVoHaL1PZvL5H_wrtEQfpNdhZ3-CPkfrMPUOytfO-ly9d1JBH8pV8GMMzs3ElYMfdmbWIcE52nwP5We5R6sYUgrfIOYkVrrHxQMjXYInx_es-HR1uVm9LW_evbleLW9KWXdsLBsNBLeqIjXm0DSyNqqtDaeGd4wRzSlTqqt7pXXPZMcV7luNG8U5M9JUWFZnxcvD3CGGrxOkUexsUuCc9BCmJEjX0pZznsHn_4DbMEWfswlKMcMNrmeIHiA1XxPBiCHanYx7QbCY7YnZnsj2RLYnKpHt5aZnx8lTvwN913LUlYEXR0AmJZ2J0iub7riWccLoPOjiwP1Z8jfef1b_Bv1UtgM</recordid><startdate>20060301</startdate><enddate>20060301</enddate><creator>Gopalakrishnan, Rajesh</creator><creator>Jacob, K.S.</creator><creator>Kuruvilla, Anju</creator><creator>Vasantharaj, B.</creator><creator>John, Jacob K.</creator><general>American Psychiatric Publishing</general><general>American Psychiatric Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7T2</scope><scope>7TK</scope><scope>7U2</scope><scope>C1K</scope></search><sort><creationdate>20060301</creationdate><title>Sildenafil in the Treatment of Antipsychotic-Induced Erectile Dysfunction: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Two-Way Crossover Trial</title><author>Gopalakrishnan, Rajesh ; Jacob, K.S. ; Kuruvilla, Anju ; Vasantharaj, B. ; John, Jacob K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a495t-6de107c31408e66a4fc74f82f89551d825cc94bcddb5a98c0b7d06c885faf30a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>3',5'-Cyclic-GMP Phosphodiesterases - therapeutic use</topic><topic>Adult</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Clinical trials</topic><topic>Comorbidity</topic><topic>Cross-Over Studies</topic><topic>Diabetes</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Drug therapy</topic><topic>Erectile Dysfunction - chemically induced</topic><topic>Erectile Dysfunction - drug therapy</topic><topic>Erectile Dysfunction - epidemiology</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>Patients</topic><topic>Pharmacology. Drug treatments</topic><topic>Physical examinations</topic><topic>Piperazines - therapeutic use</topic><topic>Placebos</topic><topic>Prolactin - blood</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Purines</topic><topic>Regression Analysis</topic><topic>Schizophrenia</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenia - epidemiology</topic><topic>Schizophrenia, Paranoid - drug therapy</topic><topic>Schizophrenia, Paranoid - epidemiology</topic><topic>Schizophrenia, Paranoid - psychology</topic><topic>Sexual behavior</topic><topic>Sexual Behavior - psychology</topic><topic>Sexual disorders</topic><topic>Sildenafil Citrate</topic><topic>Sulfones</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gopalakrishnan, Rajesh</creatorcontrib><creatorcontrib>Jacob, K.S.</creatorcontrib><creatorcontrib>Kuruvilla, Anju</creatorcontrib><creatorcontrib>Vasantharaj, B.</creatorcontrib><creatorcontrib>John, Jacob K.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Neurosciences Abstracts</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>The American journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gopalakrishnan, Rajesh</au><au>Jacob, K.S.</au><au>Kuruvilla, Anju</au><au>Vasantharaj, B.</au><au>John, Jacob K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sildenafil in the Treatment of Antipsychotic-Induced Erectile Dysfunction: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Two-Way Crossover Trial</atitle><jtitle>The American journal of psychiatry</jtitle><addtitle>Am J Psychiatry</addtitle><date>2006-03-01</date><risdate>2006</risdate><volume>163</volume><issue>3</issue><spage>494</spage><epage>499</epage><pages>494-499</pages><issn>0002-953X</issn><eissn>1535-7228</eissn><coden>AJPSAO</coden><abstract>OBJECTIVE: Antipsychotic-induced erectile dysfunction is a significant clinical problem and is a common reason for poor medication compliance. This report studied the efficacy and tolerability of sildenafil citrate in patients with antipsychotic-induced erectile dysfunction. METHOD: The study design was a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial carried out at a tertiary referral center. Thirty-two married male outpatients with schizophrenia or delusional disorder and antipsychotic-induced erectile dysfunction were recruited for the trial. Sexual function was assessed from patient logs of sexual activity. RESULTS: Thirty-two subjects and their spouses, who agreed to take part in the study, were included in the crossover trial. Thirty-one (96.9%) completed the trial. There was no significant period effect or treatment-period interaction. Patients reported significant improvement while taking sildenafil in the number of adequate erections, satisfaction with sexual intercourse, and the duration of erections over 2 weeks. The odds ratios for adequate erections and for satisfactory sexual intercourse with sildenafil were 4.07 and 3.77, respectively. The effect of sildenafil remained significant even after adjustment for period and week effects and treatment-period interaction with Poisson regression analysis. There were no major side effects or adverse drug interactions. CONCLUSIONS: Sildenafil citrate is safe and effective in the treatment of antipsychotic-induced erectile dysfunction. It is also well tolerated.</abstract><cop>Washington, DC</cop><pub>American Psychiatric Publishing</pub><pmid>16513872</pmid><doi>10.1176/appi.ajp.163.3.494</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0002-953X
ispartof The American journal of psychiatry, 2006-03, Vol.163 (3), p.494-499
issn 0002-953X
1535-7228
language eng
recordid cdi_proquest_miscellaneous_19727888
source American Psychiatric Publishing Journals (1997-Present)
subjects 3',5'-Cyclic-GMP Phosphodiesterases - therapeutic use
Adult
Antipsychotic Agents - adverse effects
Biological and medical sciences
Clinical trials
Comorbidity
Cross-Over Studies
Diabetes
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Drug therapy
Erectile Dysfunction - chemically induced
Erectile Dysfunction - drug therapy
Erectile Dysfunction - epidemiology
Follow-Up Studies
Humans
Male
Medical sciences
Middle Aged
Neuropharmacology
Patients
Pharmacology. Drug treatments
Physical examinations
Piperazines - therapeutic use
Placebos
Prolactin - blood
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Purines
Regression Analysis
Schizophrenia
Schizophrenia - drug therapy
Schizophrenia - epidemiology
Schizophrenia, Paranoid - drug therapy
Schizophrenia, Paranoid - epidemiology
Schizophrenia, Paranoid - psychology
Sexual behavior
Sexual Behavior - psychology
Sexual disorders
Sildenafil Citrate
Sulfones
Treatment Outcome
title Sildenafil in the Treatment of Antipsychotic-Induced Erectile Dysfunction: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Two-Way Crossover Trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T16%3A32%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sildenafil%20in%20the%20Treatment%20of%20Antipsychotic-Induced%20Erectile%20Dysfunction:%20A%20Randomized,%20Double-Blind,%20Placebo-Controlled,%20Flexible-Dose,%20Two-Way%20Crossover%20Trial&rft.jtitle=The%20American%20journal%20of%20psychiatry&rft.au=Gopalakrishnan,%20Rajesh&rft.date=2006-03-01&rft.volume=163&rft.issue=3&rft.spage=494&rft.epage=499&rft.pages=494-499&rft.issn=0002-953X&rft.eissn=1535-7228&rft.coden=AJPSAO&rft_id=info:doi/10.1176/appi.ajp.163.3.494&rft_dat=%3Cproquest_cross%3E1005829321%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a495t-6de107c31408e66a4fc74f82f89551d825cc94bcddb5a98c0b7d06c885faf30a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=220506048&rft_id=info:pmid/16513872&rfr_iscdi=true